Astellas Pharma, which has so far focused its corporate venturing on pharmaceuticals, and MPM Capital have formed a digital health fund called DigiTx Partners.
Japan-headquartered pharmaceutical firm Astellas Pharma formed a digital health investment fund called DigiTx Partners today as a joint venture with US-based life sciences venture capital firm MPM Capital.
DigiTx will fund digital health technology developers and in particular those capable of improving patient outcomes in synergy with a wider pharmaceutical business. The unit will prioritise early-stage companies but will consider later-stage investments as well.
The key areas in which Astellas operates are urology, oncology, immunology, nephrology and neuroscience. It already…
